secwatch.observer — SEC 8-K summary
======================================

Issuer:     INSULET CORP (PODD)
CIK:        0001145197
Form:       8-K
Filed at:   2024-11-07T23:59:59+00:00
Accession:  0001145197-24-000043
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Insulet Q3 revenue +26% to $543.9M; beats guidance; raises FY outlook; Omnipod 5 cleared for type 2 diabetes
--------------------------------------------------------------------------------

- Revenue $543.9M (+25.7% YoY); Omnipod $533.6M (+26.4%); U.S. +23.4%, International +36.1%.
- GAAP net income $77.5M ($1.08 EPS) vs $51.9M ($0.74); adjusted net income $64.2M ($0.90 EPS).
- Gross margin 69.3% (+150bps); operating income $88.1M (16.2% of revenue); adjusted EBITDA $126.1M (23.2%).
- Received FDA clearance for Omnipod 5 for type 2 diabetes; first AID system for both T1 and T2.
- Raised full-year revenue and margin guidance; Q3 revenue exceeded high end of 21% constant currency guidance.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1145197/000114519724000043/0001145197-24-000043-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1145197/000114519724000043/podd-20241107.htm
  HTML page:      https://secwatch.observer/filing/0001145197-24-000043

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer